BRG Borregaard

Borregaard ASA: Approval of Bond Prospectus

Borregaard ASA: Approval of Bond Prospectus

On 21 June 2024, the Financial Supervisory Authority of Norway approved the prospectus prepared by Borregaard in connection with the listing on the Oslo Stock Exchange of the Company’s bonds with ISIN NO0012943838.

The Prospectus is available on the company’s website:

Sarpsborg, 2 July 2024

Contact:

Director Investor Relations, Knut-Harald Bakke,

This information is subject to the disclosure requirements pursuant to Section 5 -12 the Norwegian Securities Trading Act.





EN
02/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Borregaard

 PRESS RELEASE

Borregaard ASA: Approval of Bond Prospectus

Borregaard ASA: Approval of Bond Prospectus On 21 June 2024, the Financial Supervisory Authority of Norway approved the prospectus prepared by Borregaard in connection with the listing on the Oslo Stock Exchange of the Company’s bonds with ISIN NO0012943838. The Prospectus is available on the company’s website: Sarpsborg, 2 July 2024 Contact: Director Investor Relations, Knut-Harald Bakke, This information is subject to the disclosure requirements pursuant to Section 5 -12 the Norwegian Securities Trading Act.

ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Ali Shemmari
  • Martin Melbye

Costs push prices higher

A long list of price increases as costs push prices higher. Q2e EBIT likely down q-o-q: higher maintenance costs. Smart to buy when macro is low.

ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Ali Shemmari
  • Martin Melbye

Q2 preview

Borregaard will report its next quarterly results on 17 July. We reiterate BUY with a TP of NOK 215 (205). Q2'24e EBITDA of ~NOK 500m.

Niclas Gehin
  • Niclas Gehin

Borregaard (Buy, TP: NOK210.00) - Set for continued earnings growth

We forecast Q2 EBITDA of NOK514m and EPS of NOK2.7 (results due at 07:00 CET on 17 July). We have raised our 2025–2026e EPS by 3% to reflect BioSolutions improvements and are now ~2% above Bloomberg consensus. With the stock trading at a 2025–2026e EV/EBITDA of 9.4x and 10.4x, we continue to see upside potential. We reiterate our BUY and have raised our target price to NOK210 (200).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch